ABSTRACT
Objective To study the type of disease,the optimal time and clinical effect of peripheral arteriovenous synchronous exchange transfusion in the treatment of newborns with hyperbilirubinemia. Methods The clinical data of admitted neonates with severe hyperbilirubinemia who received peripheral ar-teriovenous synchronous exchange transfusion were retrospectively analyzed from January 2015 to December 2016. Results Ninety-eight neonates were enrolled and the mean gestational age was(38. 7 ± 1. 2)weeks,the mean birth weight was(3275. 1 ± 483. 7) grams,76 cases were term infants,20 cases were preterm infants and 2 cases were post term infants. The causes of hyperbilirubinemia included 39 cases of ABO incompatibili-ty(39. 8％),16 cases of Rh incompatibility(16. 3％),3 cases of C3d incompatibility(3. 1％),2 cases of infection(2. 0％),2 cases of cranial hematoma(2. 0％),2 cases of adrenal hematoma(2. 0％) and 34 cases of unknown hyperbilirubinemia ( 34. 7％) . The mean age of exchange transfusion was ( 5. 8 ± 4. 4 ) days. Exchange transfusion removed 45. 0％ of total body bilirubin. After exchange transfusion,the total serum bili-rubin,platelet level decreased as compared with those of pre-exchange levels,the differences were statistically significant(t=15. 85,P<0. 05;t=13. 75,P<0. 05). The white blood cell counts and hemoglobin increased, the differences were statistically significant(t=4. 06,P<0. 05;t=4. 41,P<0. 05). A total of 44 cases who had bilirubin encephalopathy were compared to other 54 cases who didn't have bilirubin encephalopathy,there were no significant differences in fetal age, age of onset, bilirubin before and after blood exchange. There were significantly differences at time of exchange transfusion and the grade of hospital which the patient ad-mitted at first time(t=2. 46,P<0. 05;t=6. 15,P<0. 05). Conclusion Hemorrhagic disease is the mostimportant cause of neonatal severe hyperbilirubinemia. Clinical effect of peripheral arteriovenous synchronous exchange transfusion in the treatment of newborns with hyperbilirubinemia is obvious. Timely exchange trans-fusion can reduce the occurrence of bilirubinencephalopathy. For basic-level hospitals,it is still necessary to strengthen the implementation of hour-specific bilirubin to predict the risk of neonatal hyperbilirubinemia.
ABSTRACT
Objectives A rare case of juvenile dermatomyositis (JDM) complicated by myelodysplastic syndrome (MDS) was reported in order to improve the understanding of the disease in its clinical signs, differential diagnosis and treatment. Meth-ods The course of the disease, clinical characteristics and the process of diagnosis and treatment were analyzed. Specimens of bone marrow, lymph nodes, muscles were examined by histopathological or immunohistopathological means and lfow cytometry. Results The diagnosis of JDM complicated by MDS was made based on the clinical manifestations, related laboratory results and the accompanying changes in hematological and bone marrow examinations. Conclusions JDM complicated by MDS is very special and rarely seen in China and its pathological mechanism and strategy of diagnosis and treatment should be further explored.
ABSTRACT
The inductive conditions for the flask-shaking of E.coli BL21-pET-hBD3-Bra had been optimized, at the same time, the expressed protein had been purified and analyzed. The effect of three factors which were IPTG concentration, induction time and temperature on growth of strain and on the yield of hBD3-Bra was analyzed in detail. The result indicated that the concentration of IPTG had little effect on the growth and the expression of target protein between 0.2-1 mmol/L, Biomass would be improved as time passed, but the target protein didn't increase obviously as the same time, temperature was the most important factor, the expressed level of hBD3-Bra, as high as about 35% of total cell protein, could be gained when strain was induced by IPTG under 30 degrees C. Further analysis showed the best temperature for growth was 30 degrees C-32 degrees C and for expression protein was 30 degrees C.The purified hBD3-Bra has a weak antimicrobial activity, but is 200 times sweeter than that of sucrose. After digested by thrombin and purified by affinity column, the natural des-pGlul-Brazzein also has 600-time sweetness of sucrose, and the recombinant hBD3 has a high antimicrobial activity again E. coli and S. aureus.